Ulcerative colitis clinical trials on treatment effects: a comparison of clinical, endoscopic and histological remission (ECCO 2022)

Gastro-entérologie

15/03 - Clinical remission, defined by the Mayo Clinic Score (MCS) or modified MCS, is the accepted regulatory endpoint in drug development for ulcerative colitis (UC). Whilst histologic remission is a more stringent outcome, recent trials have reported numerically higher rates compared to endoscopic or clinical remission rates at the same timepoint, suggesting that histologic remission may be a more sensitive endpoint for detecting treatment response.